4.6 Article

Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes

Publisher

AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpgi.00216.2017

Keywords

amino acids; glucagon; hyperglucagonemia; nonalcoholic liver disease; type 2 diabetes

Funding

  1. Novo Nordisk Foundation Center for Basic Metabolic Research
  2. University of Copenhagen
  3. Novo Nordisk Foundation [13563]
  4. EliteForsk Rejsestipendiat
  5. Danish Council for Independent Research [DFF-1333-00206A]
  6. Augustinus Foundation
  7. Aase og Ejnar Danielsens Fond
  8. Maersk Fonden
  9. Holger Rabitz fond
  10. Laege Johannes Nicolaj Krogsgaard og hustru Else Krogsgaards minde-legat for medicinsk forskning og medicinske studenter ved Kobenhavns Universitet
  11. European Molecular Biology Organization (EMBO)
  12. European Foundation for the Study of Diabetes (EFSD)
  13. NNF Center for Basic Metabolic Research [Holst Group] Funding Source: researchfish
  14. Novo Nordisk Fonden [NNF15OC0016230, NNF16OC0020224, NNF18OC0031526, NNF17OC0027794, NNF12OC1015904] Funding Source: researchfish
  15. Steno Diabetes Center Copenhagen (SDCC) [SDCC 3.F CMP] Funding Source: researchfish

Ask authors/readers for more resources

Patients with type 2 diabetes (T2D) and patients with nonalcoholic fatty liver disease (NAFLD) frequently exhibit elevated plasma concentrations of glucagon (hyperglucagonemia). Hyperglucagonemia and alpha-cell hyperplasia may result from elevated levels of plasma amino acids when glucagon's action on hepatic amino acid metabolism is disrupted. We therefore measured plasma levels of glucagon and individual amino acids in patients with and without biopsy-verified NAFLD and with and without type T2D. Fasting levels of amino acids and glucagon in plasma were measured, using validated ELISAs and high-performance liquid chromatography, in obese, middle-aged individuals with I) normal glucose tolerance (NGT) and NAFLD, II) T2D and NAFLD, III) T2D without liver disease, and IV) NGT and no liver disease. Elevated levels of total amino acids were observed in participants with NAFLD and NGT compared with NGT controls (1,310 +/- 235 mu M vs. 937 +/- 281 mu M, P = 0.03) and in T2D and NAFLD compared with T2D without liver disease (1,354 +/- 329 mu M vs. 511 +/- 235 mu M, P < 0.0001). Particularly amino acids with known glucagonotropic effects (e.g., glutamine) were increased. Plasma levels of total amino acids correlated to plasma levels of glucagon also when adjusting for body mass index (BMI), glycated hemoglobin (Hb(A1c)), and cholesterol levels (beta = 0.013 +/- 0.007, P = 0.024). Elevated plasma levels of total amino acids associate with hyperglucagonemia in NAFLD patients independently of glycemic control, BMI or cholesterol - supporting the potential importance of a liver-alpha-cell axis in which glucagon regulates hepatic amino acid metabolism. Fasting hyperglucagonemia as seen in T2D may therefore represent impaired hepatic glucagon action with increasing amino acids levels. NEW & NOTEWORTHY Hypersecretion of glucagon (hyperglucagonemia) has been suggested to be linked to type 2 diabetes. Here, we show that levels of amino acids correlate with levels of glucagon. Hyperglucagonemia may depend on hepatic steatosis rather than type 2 diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available